Last reviewed · How we verify

Sulfadoxine pyrimethamine — Competitive Intelligence Brief

Sulfadoxine pyrimethamine (Sulfadoxine pyrimethamine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antifolate antimalarial. Area: Infectious Disease.

marketed Antifolate antimalarial Dihydrofolate reductase; dihydropteroate synthase Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Sulfadoxine pyrimethamine (Sulfadoxine pyrimethamine) — Radboud University Medical Center. Sulfadoxine-pyrimethamine is a fixed-dose combination of two antifolate drugs that inhibits dihydrofolate reductase and dihydropteroate synthase, blocking folate synthesis in parasites and preventing malaria and toxoplasmosis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Sulfadoxine pyrimethamine TARGET Sulfadoxine pyrimethamine Radboud University Medical Center marketed Antifolate antimalarial Dihydrofolate reductase; dihydropteroate synthase
Sulphadoxine-Pyrimethamine Sulphadoxine-Pyrimethamine ORIYOMI OMOTOYOSI AKINYOTU marketed Antifolate antimalarial Dihydrofolate reductase; dihydropteroate synthase
Sulfadoxine-pyrimethamine/folic acid Sulfadoxine-pyrimethamine/folic acid Centers for Disease Control and Prevention marketed Antifolate antimalarial Dihydrofolate reductase; dihydropteroate synthase
TMX-SMX (Bactrim(R)) TMX-SMX (Bactrim(R)) Department of Medical Services Ministry of Public Health of Thailand marketed Sulfonamide antibiotic combination Dihydrofolate reductase; dihydropteroate synthase
Quinine plus sulfadoxine-pyrimethamine Quinine plus sulfadoxine-pyrimethamine Albert Schweitzer Hospital marketed Antimalarial combination Plasmodium DNA/protein synthesis; dihydrofolate reductase; dihydropteroate synthase
Artesunate + Sulfadoxine-Pyrimethamine Artesunate + Sulfadoxine-Pyrimethamine Sanofi marketed Antimalarial combination Plasmodium falciparum (multiple targets: artemisinin-induced oxidative stress; dihydrofolate reductase; dihydropteroate synthase)
IPTp-sulphadoxine-pyrimethamine IPTp-sulphadoxine-pyrimethamine London School of Hygiene and Tropical Medicine phase 3 Antifolate antimalarial combination Dihydrofolate reductase; Dihydropteroate synthase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antifolate antimalarial class)

  1. Centers for Disease Control and Prevention · 1 drug in this class
  2. ORIYOMI OMOTOYOSI AKINYOTU · 1 drug in this class
  3. Radboud University Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sulfadoxine pyrimethamine — Competitive Intelligence Brief. https://druglandscape.com/ci/sulfadoxine-pyrimethamine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: